GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
15 nov. 2023 08h05 HE
|
GRI Bio, Inc.
Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (“IPF”) on track to start before year end 2023; Interim data expected H1 2024 Currently available treatments for IPF are...
Progress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023
14 nov. 2023 09h00 HE
|
GeoVax, Inc.
Single-Dose Protection Demonstrated Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results
13 nov. 2023 09h00 HE
|
Harvard Apparatus Regenerative Technology, Inc.
Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
13 nov. 2023 08h00 HE
|
Cocrystal Pharma, Inc.
Enrollment underway in Phase 1 trial with novel protease inhibitor CDI-988, the first potential dual coronavirus-norovirus oral antiviralDosing expected to begin later this year in Phase 2a human...
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q3 2023 Results
09 nov. 2023 14h45 HE
|
Harvard Apparatus Regenerative Technology, Inc.
HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“HRGN” or the “Company”), a clinical-stage biotechnology company developing the...
Bioxytran Gets Broad Patent Coverage on 60+ Viruses
24 oct. 2023 08h45 HE
|
BIOXYTRAN, INC.
Claims cover method of treating a viral infection with a lectin-binding carbohydrate BOSTON, MASSACHUSETTS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical...
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations
19 oct. 2023 08h30 HE
|
Imunon, Inc.
“A Tale of Two Pandemics: Lessons From the 1889 & 2019 Pandemics” presented by the Foreign Policy Association LAWRENCEVILLE, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
18 oct. 2023 08h30 HE
|
Imunon, Inc.
The MRD trial will evaluate the effect of this treatment combination on minimal residual disease. LAWRENCEVILLE, N.J., Oct. 18, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a...
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
17 oct. 2023 08h35 HE
|
GRI Bio, Inc.
UK consortia brings together internationally recognized investigators in the UK's leading centers of excellence to carry out experimental and early phase research Translational work to be...
GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions
05 oct. 2023 08h45 HE
|
GRI Bio, Inc.
In several murine models of chronic inflammation and fibrosis, as well as in humans, it has been shown that iNKT cells are selectively activated in the disease setting Data supports GRI Bio’s...